1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Cannabinoid Agonists -Pipeline Insights, 2017


DelveInsight’s, “Cannabinoid Agonists-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Cannabinoid Agonists. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Cannabinoid Agonists. DelveInsight’s Report also assesses the Cannabinoid Agonists therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
- The report provides competitive pipeline landscape of Cannabinoid Agonists
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Cannabinoid Agonists pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Cannabinoid Agonists and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Cannabinoid Agonists -Pipeline Insights, 2017
Illustrative

- Cannabinoid Agonists Overview
- Cannabinoid Agonists Disease Associated
- Cannabinoid Agonists Pipeline Therapeutics
- Cannabinoid Agonists Therapeutics under Development by Companies
- Cannabinoid Agonists Filed and Phase III Products
- Comparative Analysis
- Cannabinoid Agonists Phase II Products
- Comparative Analysis
- Cannabinoid Agonists Phase I and IND Filed Products
- Comparative Analysis
- Cannabinoid Agonists Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Cannabinoid Agonists - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Cannabinoid Agonists - Discontinued Products
- Cannabinoid Agonists - Dormant Products
- Companies Involved in Therapeutics Development for Cannabinoid Agonists
- Appendix
- Methodology
- Contact Us
- Disclaimer



List of Tables

- Number of Products under Development for Cannabinoid Agonists by Therapy Area, 2017
- Number of Products under Development for Cannabinoid Agonists, 2017
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2017
- Comparative Analysis Phase II Products, 2017
- Comparative Analysis Phase I and IND Filed Products, 2017
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017
- Drug Candidates Profiles
- Cannabinoid Agonists Assessment by Monotherapy Products
- Cannabinoid Agonists Assessment by Combination Products
- Cannabinoid Agonists Assessment by Route of Administration
- Cannabinoid Agonists Assessment by Stage and Route of Administration
- Cannabinoid Agonists Assessment by Molecule Type
- Cannabinoid Agonists Assessment by Stage and Molecule Type
- Cannabinoid Agonists Therapeutics - Discontinued Products
- Cannabinoid Agonists Therapeutics - Dormant Products
- Products under Development by Companies, 2017


List of Figures

- Number of Products under Development for Cannabinoid Agonists by Therapy Area, 2017
- Number of Products under Development for Cannabinoid Agonists, 2017
- Filed and Phase III Products, 2017
- Phase II Products, 2017
- Phase I and IND Filed Products, 2017
- Discovery and Pre-Clinical Stage Products, 2017
- Cannabinoid Agonists Assessment by Monotherapy Products
- Cannabinoid Agonists Assessment by Combination Products
- Cannabinoid Agonists Assessment by Route of Administration
- Cannabinoid Agonists Assessment by Stage and Route of Administration
- Cannabinoid Agonists Assessment by Molecule Type
- Cannabinoid Agonists Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Radiofrequency Ablation Devices for Pain Management Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Radiofrequency Ablation Devices for Pain Management Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • September 2016
  • by Transparency Market Research

Global Radiofrequency Ablation Devices for Pain Management Market: Scope and Methodology This report on radiofrequency ablation devices for pain management market studies the current as well as future ...

Cold Pain Therapy Market by Product, Application - Forecast to 2021

Cold Pain Therapy Market by Product, Application - Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global cold pain therapy market is estimated to grow at a CAGR of 5.0% from 2016 to 2021 to reach USD 1,087.7 million by 2021. The adoption of cold pain therapy products is rising across the globe ...

Pain Management Drugs and Devices - Global Market Outlook (2016-2022)

Pain Management Drugs and Devices - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • October 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Pain Management Drugs and Devices market is expected to grow from $39.48 billion in 2015 to reach $58.2 billion by 2022 with a CAGR of 5.7%. Growing various pain ...

Analgesics In Thailand

October 2016 $ 912

Download Unlimited Documents from Trusted Public Sources

Analgesic Market in the Netherlands

  • January 2017
    14 pages
  • Analgesic  

  • Netherlands  

View report >

Anti Rheumatic and Analgesic Market in Denmark

  • January 2017
    8 pages
  • Anti Rheumatic  

    Analgesic  

  • Denmark  

    Europe  

View report >

Opioid Market in the UK

  • January 2017
    12 pages
  • Opioid  

  • United Kingdom  

View report >

Related Market Segments :

Analgesic

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.